Evidence map›Paper›PMID 41862428›Full record

Trial reportAmerican journal of hematology2026

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

Nancy L Bartlett, Laurie H Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J Schuster, Sung-Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling and 11 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Nancy L BartlettSiteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
Laurie H SehnBC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, British Columbia, Canada.
Sarit AssoulineJewish General Hospital, Montreal, Quebec, Canada.
Pratyush GiriRoyal Adelaide Hospital, Adelaide, Australia.
John KuruvillaPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Stephen J SchusterLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sung-Soo YoonSeoul National University Hospital, Seoul, South Korea.
Keith FaySt Vincent's Hospital and Royal North Shore Hospital, Sydney, Australia.
Georg HessUniversity Cancer Center Mainz, University Medical School of the Johannes Gutenberg-University, Mainz, Germany.
Martin DreylingLudwig-Maximilians-University Hospital Munich, Munich, Germany.
Norma C GutierrezUniversity Hospital of Salamanca, IBSAL, Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain.ORCID 0000-0001-5834-9510
Eva CybulskiGenentech, Inc., South San Francisco, California, USA.
Fidelis SabalvaroGenentech, Inc., South San Francisco, California, USA.
Elicia PenuelGenentech, Inc., South San Francisco, California, USA.
Vanda TeodoroF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Samuel TracyGenentech, Inc., South San Francisco, California, USA.
Denison KuruvillaGenentech, Inc., South San Francisco, California, USA.
Joseph ChenGenentech, Inc., South San Francisco, California, USA.
Volker WiebkingGenentech, Inc., South San Francisco, California, USA.
Michael C WeiGenentech, Inc., South San Francisco, California, USA.
L Elizabeth BuddeCity of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0003-1464-5494

Funding

F. Hoffmann-La Roche Ltd.
6 · The paper itself

Abstract

Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed. We report the primary analysis of pharmacokinetics (PK), efficacy, and safety of mosunetuzumab SC (N = 94; median follow-up: 26.1 months) at the recommended Phase 2 dose (Cycle [C]1 Day [D]1: 5 mg; C1D8 and D15, and C2D1 onwards: 45 mg) in patients with R/R FL after ≥ 2 prior therapies, alongside data from a within-study comparator cohort of mosunetuzumab IV in a similar patient population (N = 90; median follow-up: 22.5 months). The co-primary PK endpoints (C

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalLymphoma, FollicularAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansInjections, SubcutaneousMaleMiddle AgedRecurrenceAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalbispecific antibodyfollicular lymphomasubcutaneous mosunetuzumab

Identifiers

PMID41862428
PMCPMC13055116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.